Life Insurance Corporation of India
The country’s largest insurer will list itself on the bourses on 17 May.
Aditya Birla Capital
The company said on exchanges that the firm has received a whistleblower complaint where allegations were made against Aditya Birla Sun Life and employees. The firm said an independent commission investigating the complaint did not find any merit in any allegations. The firm also said that the complaint did not level allegations against CEO Ajay Srinivasan. Srinivasan had expressed interest in taking on a new role within the group leading to him stepping down as CEO of Aditya Birla Capital. The firm also said that there have been no employee exit in Aditya Birla Capital and Aditya Birla Sun Life AMC due to the allegations.
The Vedanta Group along with its business units have been accredited as a Great Place to Work, for the second consecutive time.
The company on exchanges said it’s April gross toll collections stood at Rs 327 crore versus Rs 306.66 crore in March. The gross toll collection in April last year was at Rs 196.64 crore. The firm said on April 21 the toll collection was suspended on account of farmers’ agitation.
Maruti Suzuki India
The company has lined up Rs 5,000 crore Capex for various initiatives, including new product launches, for the current financial year.
The company won orders worth Rs 1,150 crore across its various businesses. The company said the diverse orders in the Civil business, further strengthen its portfolio diversification and reaffirm the company’s confidence in the continued strong growth of this business going forward.
The company will develop another hydropower project Arun-4 worth Rs 4,900 crore in Nepal. A Memorandum of Understanding (MoU) for the development of the 490 MW Arun-4 hydroelectric project in Nepal has been signed in Lumbini, Nepal in the presence of Prime Minister Narendra Modi and Prime Minister of Nepal Sher Bahadur Deuba, the company said in a statement.
The company on Monday reported a Rs 55 crore consolidated net loss from continuing operations for the fourth quarter. The drug firm had reported a net profit of Rs 4 crore for the January-March quarter of 2020-21 fiscal. Revenue from operations rose to Rs 810 crore for the fourth quarter compared to Rs 744 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.
The company said it reported a profit of Rs 12 crore in the March quarter from a loss of Rs 4 crore a year ago. Revenue for the quarter stood at Rs 356 crore versus Rs 243 crore last year. EBITDA was at Rs 33 crore against Rs 3 crore.